Nuvasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Co.'s principal product offering includes a minimally disruptive surgical platform, Maximum Access Surgery. The platform includes Co.'s proprietary software-driven nerve detection and avoidance systems, and Intraoperative Monitoring services and support; MaXcess, an integrated split-blade retractor system; and implants and biologics. Co.'s spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable surgeon access to the spine to perform restorative and fusion procedures. The NUVA stock yearly return is shown above.
The yearly return on the NUVA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NUVA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|